This information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you have concerns about vitamin levels, supplements, or symptoms, please speak with your NET clinical team. They can assess your individual situation and guide you safely.
What Vitamin B3 Is
Vitamin B3 — also known as niacin, nicotinamide, or nicotinic acid — is an essential water‑soluble vitamin your body uses to convert food into energy. It supports healthy skin, nerves, digestion, and plays a central role in cellular repair and NAD⁺ production, which keeps cells functioning normally.
There are two main forms:
- Nicotinic acid – affects blood vessels and cholesterol
- Nicotinamide (niacinamide) – used in most supplements; does not cause flushing
Both ultimately support the same vitamin functions.
Why Vitamin B3 Matters
Vitamin B3 is required to make NAD⁺, a molecule involved in:
- Energy production
- DNA repair
- Cellular resilience
- Detoxification pathways
Low levels can contribute to:
- Fatigue
- Skin irritation
- Digestive discomfort
- Cognitive fog
Severe deficiency leads to pellagra, though this is rare in NETs today.
How the Body Gets Vitamin B3
You obtain B3 from:
- Food (meat, fish, eggs, nuts, seeds, whole grains)
- Conversion from tryptophan, an amino acid
- Supplements, when needed
Because the body stores very little, regular intake is important.
Vitamin B3 and Neuroendocrine Tumours (NETs)
Most NET patients maintain normal Vitamin B3 levels. However, certain NET‑related factors increase the risk of deficiency.
1. Carcinoid Syndrome and Tryptophan Diversion
This mechanism is important — but clinically significant B3 deficiency is now far less common than it used to be.
Top Bullet:
Serotonin secreting NETs (carcinoid syndrome) divert tryptophan into serotonin production, leaving too little available for the body to make Vitamin B3 (niacin).
Why this matters
- Tryptophan is the raw material the body uses to make niacin
- Serotonin‑producing NETs can consume large amounts of tryptophan
- Even with a good diet, the body may not have enough left to produce niacin
- This creates a functional B3 deficiency, independent of diet
Why it’s less common today
Modern NET care has dramatically reduced the frequency of severe tryptophan diversion:
- Somatostatin analogues (SSAs) suppress serotonin production, reducing tryptophan consumption
- Earlier diagnosis means fewer patients reach extreme serotonin‑overproduction states
- Better diarrhoea control reduces nutrient loss
- Improved nutritional support catches issues earlier
Who is most at risk today?
- Patients with active, uncontrolled carcinoid syndrome
- Those with very high serotonin output
- Patients with significant diarrhoea or malabsorption
- Individuals with extensive small bowel disease or resections
For most patients on stable treatment, Vitamin B3 deficiency is uncommon, but the mechanism remains important to understand.
2. Somatostatin Analogues (SSAs)
Medications like octreotide and lanreotide can reduce absorption of several nutrients. B3 deficiency is less common than B12 or fat‑soluble vitamin issues, but still possible due to:
- Reduced digestive enzyme activity
- Reduced mucosal absorption
- Faster or slower transit depending on the patient
3. Digestive Surgery or Malabsorption
Small bowel resections, rapid transit, or chronic diarrhoea can reduce absorption of:
- Tryptophan
- Niacin itself
Because water‑soluble vitamins are not stored, even mild malabsorption can lead to deficiency over time.
Symptoms of Low Vitamin B3
Symptoms can be subtle and overlap with other conditions:
- Persistent fatigue
- Headaches
- Irritability or low mood
- Dry or inflamed skin
- Diarrhoea
- Poor appetite
- Difficulty concentrating
More significant deficiency may cause:
- Sun‑sensitive skin rashes
- Mouth soreness
- Severe diarrhoea
- Cognitive changes
Any of these warrant clinical review.
Testing Vitamin B3 Levels
There is no single routine blood test for niacin status. Clinicians may assess:
- Symptoms
- Dietary intake
- Tryptophan metabolism markers
- NAD/NADP ratios (specialist labs only)
Testing is guided by risk factors and clinical presentation.
Supplementation
Supplementation should be guided by your clinical team.
Key points:
- Nicotinamide is usually preferred for general supplementation
- Nicotinic acid can cause flushing and is mainly used for cholesterol
- High‑dose niacin can affect the liver, blood sugar, and uric acid
- Never start high‑dose niacin without medical supervision
Most people meet their needs through diet unless they have risk factors.
Food Sources of Vitamin B3
Excellent sources include:
- Chicken, turkey
- Tuna, salmon
- Beef, pork
- Peanuts, sunflower seeds
- Whole grains
- Mushrooms
- Fortified cereals
A balanced diet typically provides sufficient amounts.
When to Speak to Your Clinical Team
Contact your NET team if you experience:
- New or worsening fatigue
- Persistent diarrhoea
- Skin changes
- Cognitive fog
- Poor appetite
- Concerns about malabsorption or carcinoid syndrome
They can assess whether Vitamin B3 deficiency is contributing.
Key Takeaways
- Vitamin B3 is essential for energy, DNA repair, and cell health.
- Carcinoid syndrome can cause deficiency by diverting tryptophan into serotonin, but this is less common today due to modern treatments.
- Malabsorption and SSAs can also contribute.
- Symptoms are non‑specific, so clinical assessment is important.
- Supplementation should be supervised.
- A varied diet usually provides adequate B3.
- NET‑Specific Evidence: The NET‑related mechanisms described in this Spotlight (pancreatic insufficiency, bile acid loss, somatostatin analogue effects, steatorrhoea, and liver involvement) are supported by the 2025 ESMO review on nutritional and micronutrient considerations in neuroendocrine neoplasms. ESMO’s observations show that patients with NETs frequently have fat-soluble vitamins (ADEK) deficiencies and deficiencies of vitamin B3 and B12 that can be successfully supplemented. As long-term deficiencies in fat-soluble vitamins and vitamins B12 and B3 can cause severe symptoms, repetitive evaluation of the status of vitamins A, D, E, K, B3, and B12 and supplementation of deficiencies is recommended in patients with NETs. Citation at Reference 3 below.
Personal note
Always speak to your specialist before taking vitamin and mineral supplements — you may not need them if your levels are normal. Many NET patients assume Vitamin and Mineral deficiencies are inevitable, but with proper monitoring and management (including PERT where appropriate), levels can remain stable. A warning on taking vitamins and minerals generally. I very often see patients discussing this on my public pages and in my private group. I just wanted to say that you must always take advice from a professional, just because one patient takes a vitamin ‘x’ or mineral ‘y’, that does not mean you should take it too.
References Used
- NHS Vitamin B3 Guidance
- NIH Office of Dietary Supplements – Vitamin B3 Fact Sheet
- ESMO – Reducing deficiencies of fat-soluble vitamins, vitamin B12, and vitamin B3 in patients with neuroendocrine tumors treated with somatostatin analogues – L.D. de Hosson, S. Bunskoek, J. Stelwagen, B. Sijtema, S. Huitema, M. van Faassen, G.H. de Bock, D.J.A. de Groot, M.J.E. Campmans-Kuijpers, I.P. Kema, E.G.E. de Vries, A.M.E. Walenkamp, Volume 4, 2025, 100032, ISSN 3050-4619, https://doi.org/10.1016/j.esmorc.2025.100032. (https://www.sciencedirect.com/science/article/pii/S3050461925000310)
Thanks for reading
See also Vitamin B12 – click here
See also Vitamin B9 – click here
See the fat soluble vitamin series below
Vitamin A – click here
Vitamin D – click here
Vitamin E – click here
Vitamin K – click here
Ronny
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Click here and answer all questions to join my private Facebook group
Thanks for reading.
Ronny
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
- Ronny Allan’s Newsletter covering August 2026
Summary of August 2026 on RonnyAllan.NET August was similar to the other months of this year but like July, views are down on the previous two months due to 50% of the month spent on holiday. Still a reasonable blog performance – I can’t complain. Other key targets met were three more editions of the Spotlight… Read more: Ronny Allan’s Newsletter covering August 2026 - External Beam Radiation Therapy (EBRT) for Neuroendocrine Neoplasms
Disclaimer: The information in this section is for education only and does not represent a standard care pathway or service. These treatments are not suitable for everyone, and careful patient selection by an experienced multidisciplinary team is essential. Always discuss your individual situation with your own specialist team. External Beam Radiation Therapy (EBRT) is… Read more: External Beam Radiation Therapy (EBRT) for Neuroendocrine Neoplasms - 2026 Surveillance Update from Ronny Allan: “See you in 12 months”
It’s only a couple of weeks since I celebrated my 16th year since diagnosis of metastatic small intestine Neuroendocrine Tumour (NET) at Grade 2 on 26th July 2010. Thinking back to that period of my life, I’m happy but also slightly amazed to be celebrating such a long milestone having been diagnosed with cancer at… Read more: 2026 Surveillance Update from Ronny Allan: “See you in 12 months” - Spotlight: Selenium in Neuroendocrine Tumours (NETs)
Before you read this This information is designed to help you understand how vitamins and minerals work in the body and how certain NET‑related factors might influence them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs vary widely. If you… Read more: Spotlight: Selenium in Neuroendocrine Tumours (NETs) - Spotlight: Potassium in Neuroendocrine Tumours (NETs)
Before you read this This information is designed to help you understand how vitamins and minerals work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely.… Read more: Spotlight: Potassium in Neuroendocrine Tumours (NETs) - Spotlight: Magnesium in Neuroendocrine Tumours (NETs)
Before you read thisThis information is designed to help you understand how vitamins and minerals work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you… Read more: Spotlight: Magnesium in Neuroendocrine Tumours (NETs) - Ronny Allan’s Newsletter covering July 2026
Summary of July 2026 on RonnyAllan.NET July was similar to the other months of this year but views down on the previous two months due to 50% of the month spent on holiday. Still a reasonable blog performance. Other key targets met were three more editions of the Spotlight series on vitamins and minerals. See… Read more: Ronny Allan’s Newsletter covering July 2026 - 16 years since diagnosis, I’m still here

I finally made 16 years since I was diagnosed on 26th July 2010. A milestone I was not certain at the time I would reach. However, as things progressed, as treatment was administered, and as I got used to living with Neuroendocrine Cancer, I eventually became more confident this was a possibility with the help […]
- Spotlight on Cushing’s Syndrome in Neuroendocrine Neoplasms
Intro Cushing’s syndrome is one of the most challenging hormonal complications seen in people with neuroendocrine neoplasms (NENs). It can be subtle, severe, or even life‑threatening — and it is often misunderstood. Many patients struggle for months or years before receiving a correct diagnosis, partly because the symptoms overlap with everyday conditions such as weight… Read more: Spotlight on Cushing’s Syndrome in Neuroendocrine Neoplasms - 14th July 2026 – Ronny Allan hits 3 million blog views!
Today, 14th July 2026, I can confirm the 3 million views milestone has been reached. MASSIVE THANKS to you guys for reading and sharing. When I first set up this blog in April 2014, it was just to help spread awareness (….and collect a few pennies) whilst I was walking the 84 miles of… Read more: 14th July 2026 – Ronny Allan hits 3 million blog views! - Spotlight: Zinc in Neuroendocrine Tumours (NETs)
Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you have… Read more: Spotlight: Zinc in Neuroendocrine Tumours (NETs) - Neuroendocrine Tumours – Iron
Disclaimer: This Spotlight provides general educational information about Iron. It is not a substitute for medical advice. Individual needs vary, particularly for those with conditions affecting digestion, absorption, or chronic blood loss. Always consult your medical team before making changes to supplements or nutrition. Before I knew I had metastatic Neuroendocrine Tumours, I was diagnosed… Read more: Neuroendocrine Tumours – Iron - Ronny Allan’s Newsletter covering June 2026
Headline – half yearly point bonus edition Summary of June 2026 on RonnyAllan.NET June was similar to the other months of this year but slightly down on the previous two months due to holiday. Still a strong blog performance. Other key targets met were three more editions of the Spotlight series on primary NET types (colon, thymic… Read more: Ronny Allan’s Newsletter covering June 2026 - Clinical Trials PRRT: From 177Lu to 225Ac: The DOTA-LM3 Antagonist Journey
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over… Read more: Clinical Trials PRRT: From 177Lu to 225Ac: The DOTA-LM3 Antagonist Journey - Clinical Study from the Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the… Read more: Clinical Study from the Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET - SYHX2008: A New Self‑Injectable subcutaneous Long‑acting Octreotide on the Horizon for NETs
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the… Read more: SYHX2008: A New Self‑Injectable subcutaneous Long‑acting Octreotide on the Horizon for NETs
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.


